Trial Profile
Clinical benefits of twice daily medication of Aclidinium Bromide Compared with once daily medication of Tiotropium in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2017
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary) ; Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 24 May 2017 Primary endpoint has not been met. (FEV1AUC), according to results presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 30 Nov 2016 Status changed from active, no longer recruiting to completed.